On July 29th 2016, Journal of Biological Chemistry (JBC) retracted a cardiology paper from 2009 for data manipulations. Only some days later, on August 20th 2016, the corresponding authors Sathyamangla Naga Prasad and Sadashiva Karnik (both from the same Department of Molecular Cardiology at Cleveland Clinic in Ohio, US, submit that same paper, under same title, with only some changes, to PLOS One. All authors remained the same, only two mysteriously fell off the paper: George Calin and his former mentor Carlo Croce. The latter is a notorious cancer researcher from Ohio State University, PubPeer star accused of misconduct and author on 7 retracted papers (according to the new Retraction Watch database). Croce even made it into New York Times, which he now sues, together with his critic David Sanders. (some more details here).
It makes sense why Prasad and Karlin decided to play it safe and throw their toxic Ohio colleague Croce and his loyal former lab member Calin off their paper. They even replaced a fake western blot which caused the JBC retraction. This refurbished PLOS One paper was accepted on January 5th 2017 and published on March 22nd 2017. Now also the handling editor at PLOS has now a lot of explaining to do: Sudhiranjan Gupta, from Texas A&M University. A man who understood Prasad’s and Karnik’s dilemma, because also Gupta has his own record of gel band duplications on PubPeer, all of these incidentally with his former boss at Cleveland Clinic, Subha Sen, who in turn is co-author on both the retracted Prasad et al JBC 2009 and the new Prasad et al PLOS One 2017.
Using the free online plagiarism tool at Draftable.com, I was able to establish an extensive textual overlap, the files are available here and here. The well-known sleuth Claire Francis established figure re-use, which I document below.
Continue reading “PLOS One publishes near-copy of retracted JBC paper, sans coauthor Carlo Croce”
The Swedish Karolinska Institutet (KI) has investigated its own cell biologist and well-funded autophagy researcher Helin Vakifahmetoglu-Norberg, following my publishing of a dossier with evidence for data manipulations in her papers. Also PubPeer evidence was considered. This was a second investigation of Vakifahmetoglu-Norberg, who was fully acquitted by KI already in 2016. While the new KI investigation progressed, one of Vakifahmetoglu-Norberg’s publications was retracted (Shen et al, Oncogene 2008), due to image duplications and unavailability of original data. With their second decision, KI again exonerated Vakifahmetoglu-Norberg from all suspicions. One of the reasons was: since the Shen et al 2008 is retracted, it ceases to exist. Hence, all image duplications it shares with other Vakifahmetoglu-Norberg papers cease existing also. Other arguments were the author’s assertions to have reproduced more than 10 year old results faithfully (since the original data was unavailable), or her presenting evidence that similar looking images were in fact dissimilar. Unfortunately, where such original data could be recovered, it was shown only to internal investigators at KI, noone else. The case is closed, no appeal is possible. There will be no corrections even, unless journals do the unlikely thing and decide not to accept the KI decision.
Another Vakifahmetoglu paper (Imreh et al, J Cell Biol. 2011) is still under KI investigation but she has officially nothing to do with it. KI announced to follow this through with her former boss and the paper’s last author, Boris Zhivotovsky. He is under another KI investigation already, together with several of his colleagues including the department’s prefect Ulla Stenius (see my report here), who received the KI letter about Vakifahmetoglu whitewashing in cc. Continue reading “Data manipulation evidence in Helin Vakifahmetoglu papers “warrants no further consideration””
On June 9th 2017, the research integrity news website Retraction Watch brought an article titled: „Journal won’t look at allegations about papers more than six years old, nor from “public websites””. A public outcry followed, protesting about what was perceived an outrageous case of editorial cover-up of research fraud. The journal in question was Molecular & Cellular Biology (MCB), published by the American Society for Microbiology (ASM); the vituperative Retraction Watch article was prompted by an editorial in the June issue of this journal. The problem with that name-and-shame Retraction Watch article however was: the accusatory title did not fit their own main text at all, which did actually clarify that evidence on public websites like PubPeer is in fact very much looked at by the MCB journal editors, just not publicly commented upon. And that:
“The ASM spokesperson explained that, like the ORI, ASM journals will make exceptions to the six-year statute of limitations, for instance if older papers “provide evidence of an extensive pattern of misconduct.””
Continue reading “Journal announces to clean up past literature, gets “smeared” by Retraction Watch”
The pharma giant Pfizer announced to continue investigating the data manipulations committed by their former cancer researcher Min-Jean Yin, retractions of two more publications were requested and yet another paper’s fate is being currently decided. Again it is about studies of pharmacological inhibitors of cancer molecular pathways which Yin’s former lab at the Pfizer California research site has faked. These two retraction requests come is addition to 5 Yin retractions which Pfizer already announced on my site in October 2016 and which meanwhile happened. The PubPeer-listed evidence was first presented on my site in May 2016. Back then, the reader of my site, who posted that evidence of duplicated western blots on PubPeer and alerted me to it, preferred to remain unnamed. Now however, she agreed to be named: it was the microbiologist, image integrity specialist and host of the successful public outreach blog Microbiome Digest, Elisabeth Bik. She now forwarded to me this message: Continue reading “Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed”
Arthur Caplan, internationally respected professor of bioethics and director of the Division of Medical Ethics at the New York University, requested publicly retractions of the bioethics reviews on regenerative medicine he co-authored with the scandal surgeon Paolo Macchiarini. Caplan notified the journals with his retraction requests, but said to have received no response from them yet. Not only this: Caplan calls for all works of Macchiarini to be retracted.
Macchiarini is now an international pariah, he recently again lost his job, this time with the Kazan Federal University in Russia (see my report). His publications are under investigation at his former workplace the Karolinska Institutet in Stockholm (where he was previously sacked), the Swedish state announced to soon charge him with manslaughter, due to 3 lethal plastic trachea transplants he performed at Karolinska. Continue reading “Bioethicist Arthur Caplan calls for retraction of all Macchiarini papers”
Four private scientists without any agenda whatsoever published a research result preprint on the portal BioRxiv. The “new results” reported in the article are actually new ideas which are just as good as any research results, because they are supposed to bring the field of scholarly communication forward. The question is, where to, and why should anyone go there. Because the idea is to abolish the only tool science now has at hand to punish research misconduct: retractions. Fraudulent papers are to receive instead an amendment, which will notify those particularly inclined readers that research data or ethics approval (for clinical studies) might have been falsified or missing. Those proposing to remove the only punitive measure available in scholarly publishing are in fact the very people who are supposed to be overseeing the editorial integrity. The goats whom science welcomed as gardeners now dropped the pretence and declared their true vision for the garden. Continue reading “COPE, the publishers’ Trojan horse, calls to abolish retractions”
The misconduct-tainted paper on oesophagus transplants in rats (Sjöqvist et al 2014) by the fallen star of regenerative medicine Paolo Macchiarini is finally retracted by the journal Nature Communications. This happens after Swedish investigations found the authors (primarily the scandal thorax surgeon and his right-hand man Philipp Jungebluth) guilty of data manipulation and research misconduct in September 2016 and after the Karolinska Institutet (KI) shortly before Christmas publicly demanded a retraction (see my report here). Today’s retraction is a major setback for Macchiarini, since his current employment and funding at the Federal University of Kazan (KFU) in Russia depend on his experiments with oesophageal transplants in primates (see my reports here and here). That Russian project was in turn only possible because of Macchiarini’s allegedly successful experiments in rats, published in a prestige journal with “Nature” in its title. This paper’s retraction is therefore probably only the beginning of a whole looming avalanche of bad news for Macchiarini and his acolyte Jungebluth (who currently sues me in court). An expert review of their publication Jungebluth et al 2015 declares the findings of misconduct, ethics breach and patient abuse. The report however has yet to be confirmed by a commission at the Swedish Central Ethics Review Board (CEPN) and then formulated as an official decree by the KI. I publish the expert reviewer report below. Continue reading “Updated: Retraction, and another looming misconduct finding for Macchiarini and Jungebluth”